ProMIS Neurosciences (PMN) Interest Expenses (2021 - 2026)
ProMIS Neurosciences' (PMN) quarterly Interest Expenses came in at $71560.0 in Q1 2026, down 99.83% on a QoQ basis from $41.0 million in Q4 2025.
ProMIS Neurosciences (PMN) Interest Expenses (2021 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 6 years of Interest Expenses data on file, last reported at $71560.0 in Q1 2026.
- Quarterly Interest Expenses changed N/A year-over-year to $71560.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71560.0 (down 52.99% YoY) and the FY2025 annual result came in at $41.0 million, up 28.61% from the prior year.
- Interest Expenses declined to $71560.0 in Q1 2026, from $41.0 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $41.0 million in Q4 2025 to a low of $4842.0 in Q3 2022.
- A 5-year average of $3.8 million and a median of $75413.0 in 2023 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses sank 96.56% — and 2023, when it jumped 1457.48%.
- Tracing PMN's Interest Expenses over 5 years: stood at $4842.0 in 2022, then soared by 1486.02% to $76795.0 in 2023, then sank by 79.17% to $16000.0 in 2024, then jumped by 256185.76% to $41.0 million in 2025, then sank by 99.83% to $71560.0 in 2026.
- The last three Interest Expenses figures came in at $71560.0 (Q1 2026), $41.0 million (Q4 2025), and $16000.0 (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | ProMIS Neurosciences | 132.34 Mn | 78.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.14 Mn |
| Jun 30, 2026 | 2.14 Mn |
| Mar 31, 2026 | 71,560.00 |
| Mar 31, 2026 | 71,560.00 |
| Dec 31, 2025 | 41.01 Mn |
| Dec 31, 2025 | 41.01 Mn |
| Sep 30, 2024 | 16,000.00 |
| Sep 30, 2024 | 16,000.00 |
| Jun 30, 2024 | 66,000.00 |
| Jun 30, 2024 | 66,000.00 |
| Mar 31, 2024 | 150,760.00 |
| Mar 31, 2024 | 150,760.00 |
| Dec 31, 2023 | 76,795.00 |
| Dec 31, 2023 | 76,795.00 |
| Sep 30, 2023 | 75,413.00 |
| Sep 30, 2023 | 75,413.00 |
| Jun 30, 2023 | 49,182.00 |
| Jun 30, 2023 | 49,182.00 |
| Sep 30, 2022 | 4,842.00 |
| Sep 30, 2022 | 4,842.00 |